DRUG · Unmapped registry intervention
Icotinib
Find medicine records ·
Find other trials using this name
Clinical trial
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
NCT05132985
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Cisplatin
Normalized identity: cisplatinView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Carboplatin
Normalized identity: carboplatinView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Pemetrexed
Normalized identity: pemetrexedView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedNeoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
NSCLCverified · MONDO: non-small cell lung carcinoma
Interventions
IcotinibDRUG
CisplatinDRUG · verified · RxNorm: cisplatin
CarboplatinDRUG · verified · RxNorm: carboplatin
PemetrexedDRUG · verified · RxNorm: pemetrexed
Sponsors & collaborators
Liaoning Cancer Hospital & Institutelead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05132985 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.